Amedeo Smart

Free Medical Literature Service

 

Amedeo

Lung Cancer
  Free Subscription

Articles published in
JAMA Oncol
    October 2025
  1. LIN JK, Xu Y, Xiang JJ, Singhi EK, et al
    Nationwide Response to Carboplatin and Cisplatin Shortages in Lung Cancer.
    JAMA Oncol. 2025 Oct 2:e253768. doi: 10.1001/jamaoncol.2025.3768.
    >> Share

    September 2025
  2. ANTONOFF MB, Phillips L, Singhi EK
    Understanding Lung Cancer in Younger People.
    JAMA Oncol. 2025 Sep 25. doi: 10.1001/jamaoncol.2025.3320.
    >> Share

  3. DI Y, Song Z, Meng L
    Neoadjuvant Chemoimmunotherapy in Stage III Non-Small Cell Lung Cancer.
    JAMA Oncol. 2025 Sep 18. doi: 10.1001/jamaoncol.2025.3491.
    >> Share

  4. BERTOLACCINI L, de Marinis F, Spaggiari L
    Neoadjuvant Chemoimmunotherapy in Stage III Non-Small Cell Lung Cancer.
    JAMA Oncol. 2025 Sep 18. doi: 10.1001/jamaoncol.2025.3494.
    >> Share

  5. GARBO E, Ricciuti B, Cappuzzo F
    Neoadjuvant Chemoimmunotherapy in Stage III Non-Small Cell Lung Cancer-Reply.
    JAMA Oncol. 2025 Sep 18. doi: 10.1001/jamaoncol.2025.3497.
    >> Share

  6. JONGBLOED M, Bortolot M, Willmann J, Bartolomeo V, et al
    Current Controversies and Challenges in Non-Oncogene-Addicted Synchronous Oligometastatic Non-Small Cell Lung Cancer: A Review.
    JAMA Oncol. 2025 Sep 4. doi: 10.1001/jamaoncol.2025.2891.
    >> Share

    August 2025
  7. ROLLE LD, Crane TE
    Methodological Concerns With Lung Cancer Screening Estimates-Reply.
    JAMA Oncol. 2025 Aug 14. doi: 10.1001/jamaoncol.2025.2581.
    >> Share

  8. BURUS T, McAfee CR, Hull PC
    Methodological Concerns With Lung Cancer Screening Estimates.
    JAMA Oncol. 2025 Aug 14. doi: 10.1001/jamaoncol.2025.2584.
    >> Share

    June 2025
  9. MARKS JA, Liu SV
    Navigating Selective Dose Intensification in EGFR-Variant Non-Small Cell Lung Cancer.
    JAMA Oncol. 2025 Jun 26. doi: 10.1001/jamaoncol.2025.1768.
    >> Share

  10. LI H, Chen K, Gong L, Qin J, et al
    High-Dose Aumolertinib for Untreated EGFR-Variant Non-Small Cell Lung Cancer With Brain Metastases: The ACHIEVE Phase 2 Nonrandomized Clinical Trial.
    JAMA Oncol. 2025 Jun 26. doi: 10.1001/jamaoncol.2025.1779.
    >> Share

    May 2025
  11. ROLLE LD
    Coding Errors in Study of Lung Cancer Screening Guidelines and Adherence.
    JAMA Oncol. 2025 May 29. doi: 10.1001/jamaoncol.2025.1624.
    >> Share

  12. MARINELLO A, Ghigna MR, Rotow JK, Adeyelu T, et al
    Expression of Membrane Targets for Therapeutics in RET-Positive Non-Small Cell Lung Cancer.
    JAMA Oncol. 2025 May 29. doi: 10.1001/jamaoncol.2025.1293.
    >> Share

  13. RICCIUTI B, Fusco F, Cooper A, Garbo E, et al
    Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung Cancer.
    JAMA Oncol. 2025 May 22. doi: 10.1001/jamaoncol.2025.1115.
    >> Share

  14. HEYWARD J, Lesko CR, Murray JC, Mehta HB, et al
    Harm-Benefit Balance of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    JAMA Oncol. 2025 May 8. doi: 10.1001/jamaoncol.2025.0985.
    >> Share

    April 2025
  15. PIKE LRG, Yu H, Rusthoven CG
    Management of EGFR-Variant and ALK-Positive Non-Small Cell Lung Cancer Brain Metastasis.
    JAMA Oncol. 2025 Apr 3. doi: 10.1001/jamaoncol.2025.0188.
    >> Share

    March 2025
  16. ROLLE LD, Olazagasti C, Lopes G, Rodriguez E, et al
    USPSTF Lung Cancer Screening Guidelines and Disparities in Screening Adherence.
    JAMA Oncol. 2025 Mar 20. doi: 10.1001/jamaoncol.2025.0230.
    >> Share

    February 2025
  17. SAAL J, Eckstein M, Ritter M, Brossart P, et al
    Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy.
    JAMA Oncol. 2025;11:154-161.
    >> Share

  18. GODDARD KAB, Feuer EJ, Mandelblatt JS, Meza R, et al
    Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020.
    JAMA Oncol. 2025;11:162-167.
    >> Share

    December 2024
  19. RAKAEE M, Tafavvoghi M, Ricciuti B, Alessi JV, et al
    Deep Learning Model for Predicting Immunotherapy Response in Advanced Non-Small Cell Lung Cancer.
    JAMA Oncol. 2024 Dec 26. doi: 10.1001/jamaoncol.2024.5356.
    >> Share

    November 2024
  20. MALHOTRA J, Mambetsariev I, Gilmore G, Fricke J, et al
    Targeting CNS Metastases in Non-Small Cell Lung Cancer With Evolving Approaches Using Molecular Markers: A Review.
    JAMA Oncol. 2024 Nov 27. doi: 10.1001/jamaoncol.2024.5218.
    >> Share

  21. CHENG Y, Zhang W, Wu L, Zhou C, et al
    Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical Trial.
    JAMA Oncol. 2024 Nov 14. doi: 10.1001/jamaoncol.2024.5019.
    >> Share

  22. CALI DAYLAN AE, Morgensztern D, Waqar SN
    Toripalimab For Extensive-Stage Small Cell Lung Cancer.
    JAMA Oncol. 2024 Nov 14. doi: 10.1001/jamaoncol.2024.4958.
    >> Share

    October 2024
  23. ASAHINA H, Tsukita Y, Tozuka T
    Chemoimmunotherapy in Older Adults With Non-Small Cell Lung Cancer-Reply.
    JAMA Oncol. 2024 Oct 24. doi: 10.1001/jamaoncol.2024.4757.
    >> Share

  24. TU H, Zhang Y, You Z
    Chemoimmunotherapy in Older Adults With Non-Small Cell Lung Cancer.
    JAMA Oncol. 2024 Oct 24. doi: 10.1001/jamaoncol.2024.4754.
    >> Share

    September 2024
  25. ZHANG L, Li J, Guo L
    Meta-Analysis Methods for Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung Cancer.
    JAMA Oncol. 2024 Sep 26. doi: 10.1001/jamaoncol.2024.4211.
    >> Share

  26. SORIN M, Prosty C, Spicer JD
    Meta-Analysis Methods for Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung Cancer-Reply.
    JAMA Oncol. 2024 Sep 26. doi: 10.1001/jamaoncol.2024.4214.
    >> Share

  27. HU C
    Stereotactic Body Radiotherapy for Medically Inoperable Early-Stage Non-Small Cell Lung Cancer.
    JAMA Oncol. 2024 Sep 19. doi: 10.1001/jamaoncol.2024.2905.
    >> Share

  28. SWAMINATH A, Parpia S, Wierzbicki M, Kundapur V, et al
    Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I Non-Small Cell Lung Cancer: The LUSTRE Phase 3 Randomized Clinical Trial.
    JAMA Oncol. 2024 Sep 19:e243089. doi: 10.1001/jamaoncol.2024.3089.
    >> Share

    August 2024
  29. HONG MH, Choi YJ, Ahn HK, Lim SM, et al
    Lazertinib in EGFR-Variant Non-Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors: A Nonrandomized Controlled Trial.
    JAMA Oncol. 2024 Aug 15. doi: 10.1001/jamaoncol.2024.2640.
    >> Share

  30. CHENG H
    The Role of Lazertinib in Patients With EGFR-Variant Non-Small Cell Lung Cancer.
    JAMA Oncol. 2024 Aug 15. doi: 10.1001/jamaoncol.2024.2607.
    >> Share

  31. HATTON JN, Kucera J, Seastedt KP, de Andrade KC, et al
    Characterizing Lung Cancer in Li-Fraumeni Syndrome.
    JAMA Oncol. 2024 Aug 1:e242511. doi: 10.1001/jamaoncol.2024.2511.
    >> Share

  32. LEE JM
    Sublobar Resection vs Lobectomy for High-Risk Stage I Non-Small Cell Lung Carcinoma.
    JAMA Oncol. 2024 Aug 1. doi: 10.1001/jamaoncol.2024.2294.
    >> Share

  33. ALTORKI N, Wang X, Damman B, Jones DR, et al
    Recurrence of Non-Small Cell Lung Cancer With Visceral Pleural Invasion: A Seconday Analysis of a Randomized Clinical Trial.
    JAMA Oncol. 2024 Aug 1:e242491. doi: 10.1001/jamaoncol.2024.2491.
    >> Share

    July 2024
  34. ROSS HJ, Kozono D, Wang XF, Urbanic JJ, et al
    Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase II Nonrandomized Controlled Trial.
    JAMA Oncol. 2024 Jul 25. doi: 10.1001/jamaoncol.2024.1897.
    >> Share

  35. TSAI CH, Chiang PH
    More Benefits of Tai Chi Than Aerobic Exercise in Patients With Advanced Lung Cancer.
    JAMA Oncol. 2024 Jul 3. doi: 10.1001/jamaoncol.2024.2453.
    >> Share

  36. TAKEMURA N, Lin CC
    More Benefits of Tai Chi Than Aerobic Exercise in Patients With Advanced Lung Cancer-Reply.
    JAMA Oncol. 2024 Jul 3. doi: 10.1001/jamaoncol.2024.2456.
    >> Share

    June 2024
  37. CHUN SG, Hu C, Komaki RU, Timmerman RD, et al
    Long-Term Prospective Outcomes of Intensity Modulated Radiotherapy for Locally Advanced Lung Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    JAMA Oncol. 2024 Jun 27. doi: 10.1001/jamaoncol.2024.1841.
    >> Share

  38. DONG S, Wang Z, Zhang JT, Yan B, et al
    Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non-Small Cell Lung Cancer: A Nonrandomized Clinical Trial.
    JAMA Oncol. 2024 Jun 13. doi: 10.1001/jamaoncol.2024.1779.
    >> Share

    May 2024
  39. CHAUNZWA TL, Qian JM, Li Q, Ricciuti B, et al
    Body Composition in Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy.
    JAMA Oncol. 2024 May 23. doi: 10.1001/jamaoncol.2024.1120.
    >> Share

  40. SORIN M, Prosty C, Ghaleb L, Nie K, et al
    Neoadjuvant Chemoimmunotherapy for NSCLC: A Systematic Review and Meta-Analysis.
    JAMA Oncol. 2024;10:621-633.
    >> Share

  41. ROLFO C, Russo A
    The Chemoimmunotherapy Revolution in Resectable NSCLC-The Times They Are A-Changin'.
    JAMA Oncol. 2024;10:569-570.
    >> Share

    April 2024
  42. NORONHA V, Patil V, Menon N, Shah M, et al
    Gefitinib vs Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Variant Lung Cancer-Long-Term Results of a Randomized Clinical Trial.
    JAMA Oncol. 2024 Apr 25. doi: 10.1001/jamaoncol.2024.0584.
    >> Share

  43. RODRIGUES G, Higgins KA, Rimner A, Amini A, et al
    American Radium Society Appropriate Use Criteria for Unresectable Locally Advanced Non-Small Cell Lung Cancer.
    JAMA Oncol. 2024 Apr 11. doi: 10.1001/jamaoncol.2024.0294.
    >> Share

  44. AKAMATSU H
    Locally Advanced Relapse May Not Be Equal to Stage 3 Non-Small Cell Lung Cancer.
    JAMA Oncol. 2024 Apr 4. doi: 10.1001/jamaoncol.2024.0231.
    >> Share

  45. TACHIHARA M, Tsujino K
    Locally Advanced Relapse May Not Be Equal to Stage 3 Non-Small Cell Lung Cancer-Reply.
    JAMA Oncol. 2024 Apr 4. doi: 10.1001/jamaoncol.2024.0234.
    >> Share

  46. SZLOSAREK PW, Creelan BC, Sarkodie T, Nolan L, et al
    Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial.
    JAMA Oncol. 2024;10:475-483.
    >> Share

    March 2024
  47. ITO K, Suzuki Y, Sakaguchi T, Fujiwara K, et al
    Physical Activity Using a Wearable Device as an Alternative to Performance Status in Patients With Advanced Lung Cancer.
    JAMA Oncol. 2024 Mar 28. doi: 10.1001/jamaoncol.2024.0023.
    >> Share

  48. TSUKITA Y, Tozuka T, Kushiro K, Hosokawa S, et al
    Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non-Small Cell Lung Cancer.
    JAMA Oncol. 2024 Mar 7. doi: 10.1001/jamaoncol.2023.6277.
    >> Share

  49. PALMA DA, Bahig H, Hope A, Harrow S, et al
    Stereotactic Radiation Therapy in Early Non-Small Cell Lung Cancer and Interstitial Lung Disease: A Nonrandomized Clinical Trial.
    JAMA Oncol. 2024 Mar 7. doi: 10.1001/jamaoncol.2023.7269.
    >> Share

  50. KEREKES DM, Frey AE, Prsic EH, Tran TT, et al
    Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US.
    JAMA Oncol. 2024;10:342-351.
    >> Share

    January 2024
  51. ARRIETA O, Cardenas-Fernandez D, Rodriguez-Mayoral O, Gutierrez-Torres S, et al
    Mirtazapine as Appetite Stimulant in Patients With Non-Small Cell Lung Cancer and Anorexia: A Randomized Clinical Trial.
    JAMA Oncol. 2024 Jan 11. doi: 10.1001/jamaoncol.2023.5232.
    >> Share

  52. LESTER-COLL NH, Park HS
    Stereotactic Body Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer-Is This the Future?
    JAMA Oncol. 2024 Jan 11. doi: 10.1001/jamaoncol.2023.5856.
    >> Share

  53. WU TC, Luterstein E, Neilsen BK, Goldman JW, et al
    Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
    JAMA Oncol. 2024 Jan 11. doi: 10.1001/jamaoncol.2023.6033.
    >> Share

  54. NOGUEIRA LM, Liu Y
    Wildfire Exposure and Lung Cancer Survival-Reply.
    JAMA Oncol. 2024 Jan 4. doi: 10.1001/jamaoncol.2023.6126.
    >> Share

  55. OZAKI A, Murakami M, Leppold C
    Wildfire Exposure and Lung Cancer Survival.
    JAMA Oncol. 2024 Jan 4. doi: 10.1001/jamaoncol.2023.6123.
    >> Share

  56. OKUMA Y, Kubota K, Shimokawa M, Hashimoto K, et al
    First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial.
    JAMA Oncol. 2024;10:43-51.
    >> Share

    December 2023
  57. WEST HJ, Kim JY
    Rapid Advances in Resectable Non-Small Cell Lung Cancer: A Narrative Review.
    JAMA Oncol. 2023 Dec 28. doi: 10.1001/jamaoncol.2023.5276.
    >> Share

  58. SHIRAISHI Y, Kishimoto J, Sugawara S, Mizutani H, et al
    Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
    JAMA Oncol. 2023 Dec 21. doi: 10.1001/jamaoncol.2023.5258.
    >> Share

  59. TEWARI KS, Colombo N, Monk BJ, Dubot C, et al
    Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses from the KEYNOTE-826 Randomized Clinical Trial.
    JAMA Oncol. 2023 Dec 14. doi: 10.1001/jamaoncol.2023.5410.
    >> Share

  60. TAKEMURA N, Cheung DST, Fong DYT, Lee AWM, et al
    Effectiveness of Aerobic Exercise and Tai Chi Interventions on Sleep Quality in Patients With Advanced Lung Cancer: A Randomized Clinical Trial.
    JAMA Oncol. 2023 Dec 7. doi: 10.1001/jamaoncol.2023.5248.
    >> Share

    November 2023
  61. BONNER SN, Curley R, Love K, Akande T, et al
    Structural Racism and Lung Cancer Risk: A Scoping Review.
    JAMA Oncol. 2023 Nov 30. doi: 10.1001/jamaoncol.2023.4897.
    >> Share

  62. WANG VE, Gainor JF
    Osimertinib in Patients With Non-Small Cell Lung Cancer and Uncommon EGFR Mutations-Chasing Unicorns?
    JAMA Oncol. 2023 Nov 22. doi: 10.1001/jamaoncol.2023.5004.
    >> Share

  63. KIM TW, Bedard PL, LoRusso P, Gordon MS, et al
    Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial.
    JAMA Oncol. 2023;9:1574-1582.
    >> Share

  64. GENSHEIMER MF, Gee H, Shirato H, Taguchi H, et al
    Individualized Stereotactic Ablative Radiotherapy for Lung Tumors: The iSABR Phase 2 Nonrandomized Controlled Trial.
    JAMA Oncol. 2023;9:1525-1534.
    >> Share

    October 2023
  65. CHOI E, Ding VY, Luo SJ, Ten Haaf K, et al
    Risk Model-Based Lung Cancer Screening and Racial and Ethnic Disparities in the US.
    JAMA Oncol. 2023 Oct 26. doi: 10.1001/jamaoncol.2023.4447.
    >> Share

  66. SEQUIST LV, Warner ET, Yang CJ
    Improving Eligibility Criteria for Lung Cancer Screening-Promises, Challenges, and Unmet Needs.
    JAMA Oncol. 2023 Oct 26. doi: 10.1001/jamaoncol.2023.4410.
    >> Share

  67. JEMAL A, Schafer EJ, Sung H, Bandi P, et al
    The Burden of Lung Cancer in Women Compared With Men in the US.
    JAMA Oncol. 2023 Oct 12. doi: 10.1001/jamaoncol.2023.4415.
    >> Share

  68. TAKAHASHI N, Hao Z, Villaruz LC, Zhang J, et al
    Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer: A Randomized Clinical Trial.
    JAMA Oncol. 2023 Oct 12. doi: 10.1001/jamaoncol.2023.4025.
    >> Share

    September 2023
  69. ALDEA M, Marinello A, Guyon D, Gazzah A, et al
    Prevalence of Thromboembolic Events in Patients With Non-Small Cell Lung Cancer and RET Fusions.
    JAMA Oncol. 2023 Sep 14. doi: 10.1001/jamaoncol.2023.3625.
    >> Share

  70. TACHIHARA M, Tsujino K, Ishihara T, Hayashi H, et al
    Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial.
    JAMA Oncol. 2023 Sep 7. doi: 10.1001/jamaoncol.2023.3309.
    >> Share

  71. GRECO L
    Patients With Brain Metastases Deserve Better-A Hard-Won Perspective.
    JAMA Oncol. 2023;9:1197-1198.
    >> Share

  72. SPAAS M, Sundahl N, Kruse V, Rottey S, et al
    Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial.
    JAMA Oncol. 2023;9:1205-1213.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016